Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 3

Behavior and neuropsychiatric manifestations in Angelman syndrome

Authors Karine Pelc, Guy Cheron, Bernard Dan

Published Date June 2008 Volume 2008:4(3) Pages 577—584

DOI http://dx.doi.org/10.2147/NDT.S2749

Published 30 June 2008

Karine Pelc1, Guy Cheron2, Bernard Dan1,2

1Department of Neurology, Hôpital Universitaire des Enfants Reine Fabiola, Université Libre de Bruxelles (ULB), Brussels, Belgium; 2Laboratory of Neurophysiology and Movement Biomechanics, Université Libre de Bruxelles (ULB), Brussels, Belgium

Abstract: Angelman syndrome has been suggested as a disease model of neurogenetic developmental condition with a specific behavioral phenotype. It is due to lack of expression of the UBE3A gene, an imprinted gene located on chromosome 15q. Here we review the main features of this phenotype, characterized by happy demeanor with prominent smiling, poorly specific laughing and general exuberance, associated with hypermotor behavior, stereotypies, and reduced behavioral adaptive skills despite proactive social contact. All these phenotypic characteristics are currently difficult to quantify and have been subject to some differences in interpretation. For example, prevalence of autistic disorder is still debated. Many of these features may occur in other syndromic or nonsyndromic forms of severe intellectual disability, but their combination, with particularly prominent laughter and smiling may be specific of Angelman syndrome. Management of problematic behaviors is primarily based on behavioral approaches, though psychoactive medication (eg, neuroleptics or antidepressants) may be required.

Keywords: Angelman syndrome, UBE3A, chromosome 15, behavioral phenotypes, autism, neurogenetics

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

The effect of blood protein adsorption on cellular uptake of anatase TiO2 nanoparticles

Allouni ZE, Gjerdet NR, Cimpan MR, Høl PJ

International Journal of Nanomedicine 2015, 10:687-695

Published Date: 19 January 2015

Direct electrochemical oxidation of S-captopril using gold electrodes modified with graphene-AuAg nanocomposites

Pogacean F, Biris AR, Coros M, Lazar MD, Watanabe F, Kannarpady GK, Al Said SA Farha, Biris AS, Pruneanu S

International Journal of Nanomedicine 2014, 9:1111-1125

Published Date: 25 February 2014

The Nanomaterial Registry: facilitating the sharing and analysis of data in the diverse nanomaterial community

Ostraat ML, Mills KC, Guzan KA, Murry D

International Journal of Nanomedicine 2013, 8:7-13

Published Date: 16 September 2013

Nanoparticles and their potential for application in bone

Tautzenberger A, Kovtun A, Ignatius A

International Journal of Nanomedicine 2012, 7:4545-4557

Published Date: 17 August 2012

The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals

Men Y, Wang XX, Li RJ, Zhang Y, Tian W, Yao HJ, Ju RJ, Ying X, Zhou J, Li N, Zhang L, Yu Y, Lu WL

International Journal of Nanomedicine 2011, 6:3125-3137

Published Date: 2 December 2011

Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells

Laurent Brard, Rakesh K Singh, Kyu Kwang Kim, Thilo S Lange, Giselle L Saulier Sholler

Drug Design, Development and Therapy 2008, 2:61-69

Published Date: 9 April 2008

Determinants of outcome in patients eligible for thrombolysis for ischemic stroke

Valeria Caso, Maurizio Paciaroni, Michele Venti, Francesco Palmerini, Giorgio Silvestrelli, et al

Vascular Health and Risk Management 2007, 3:749-754

Published Date: 21 November 2007